BrainStorm Cell Therapeutics Announces Adult Stem Cell Breakthrough for Neurodegenerative Diseases(18llowing on from the widely reported treatment of Parkinson's patients in Bristol using the drug GDNF, Israeli researchers working at Tel Aviv University with the company BrainStorm Cell Therapeutics, have successfully derived sufficient amounts of glial derived neurotrophic factor (GDNF) from human bone-marrow-derived mesenchymal-stem cells. This breakthrough is significant as it demonstrates that it is possible to create GDNF cells from the patient's own body which means that they will not be rejected after transplantation. In addition to protecting and regenerating dopaminergic brain cells in parkinson's patients, GDNF has also been demonstrated to be beneficial in animal models of Amyotrophic Lateral Sclerosis and Spinal Cord Injury.